Loading company
Bright Minds Biosciences Inc.
DRUG · Nasdaq · ·
$49.67-3.8%Sep 29 close
- 1M
- -31.8%
- 6M
- -27.4%
- 1Y
- -18.1%
Trailing twelve months where a flow is involved, latest reported balance where it is not.
Both on one scale, because both are money — the bar that is taller is the one that matters.
Cash counts short-term investments, not just the bank balance — technology companies park most of it in marketable securities, and leaving those out understates it several times over. Debt includes lease obligations.
Only the three costs filers report consistently. Anything a company does not break out sits outside these bands, so the stack is not the whole cost base.
Not on the overview because five charts is as much as one decision needs — but here in full, on one period switch. One bar per fiscal year, as filed. Stops at the last completed year.
-$8.62M2025-336.5%
What was left after every cost, including tax. One bar per fiscal year, as filed. Stops at the last completed year.
-$0.462024+67.2%
The same profit, split across every share. If this lags the profit chart above, the company is issuing shares and your slice is getting smaller. Restated onto today’s share count, so stock splits do not show as jumps. One bar per fiscal year, as filed. Stops at the last completed year.
6.88M2025+59.6%
How many shares the profit is divided across. Rising is dilution; falling is the company buying itself back. Restated onto today’s basis, so splits do not show as jumps. One point per fiscal year, as filed. Stops at the last completed year.
Everything above comes from Bright Minds Biosciences Inc.’s own filings with the SEC, as reported. No estimates, no analyst figures, nothing adjusted.
Share-count jumps we cannot explain: 0.50x around Sep 30, 2021, 1.51x around Sep 30, 2023, and 1.60x around Sep 30, 2025. No split accounts for these, so nothing was adjusted — most often it is real dilution rather than a data problem, which is why it is flagged and not corrected.
Not reported by this filer: Total Revenue, Cost of Revenue, Gross Profit, Total Operating Expenses, Operating Income, Interest Expense, Net Interest Income, Non-interest Income, Non-interest Expense, Provision for Credit Losses, Deposits, Loans, Short-term Investments, Inventory, Receivables, Long-term Debt (noncurrent), Long-term Debt (current), Short-term Borrowings, Borrowings (total), Finance Lease (current), Finance Lease Liabilities (total), Finance Lease (noncurrent), Capital Expenditures, Investing Cash Flow, Dividends paid, Depreciation, Amortization of Intangibles, and Share Repurchases. Companies choose which XBRL tags to use, and anything untagged cannot be recovered — so these are blank rather than guessed.
DRUG · Nasdaq · ·
$49.67-3.8%Sep 29 close